Skip to content
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

Model For Economic Analysis of Sickle Cell Cure (Measure)

Background and Objectives

Approximately 100,000 Americans have Sickle Cell Disease (SCD), a group of single-gene, autosomal recessive disorders that affect hemoglobin (Hb) structure and function. While treatment strides have been made, resulting in increased life expectancy and reduced disease complications, those with the most severe forms of SCD still have lifespans of 20-30 years shorter than those without SCD. Further, those living with SCD experience significant health and economic burden due to their disease. Currently, a wide array of approaches to curative gene therapy is being pursued in clinical trials, animal models, and tissue culture systems. While promising, the risks to patients vs. ultimate short and long-term benefits remain contested and largely unknown for these therapies.

Project Aims:

Aim 1: Conduct a landscape analysis for cost-of-illness studies in SCD and cost-effectiveness analysis of genetic therapies for SCD

We will carry out a landscape analysis to identify studies that estimate the cost of illness estimates for SCD, and, separately, studies that estimate the cost-effectiveness of emerging therapies for SCD. We will use established systematic review methods to search both the published and grey literature and publish our findings, as well as use them to inform our conceptual model.

Aim2: Develop a simulation model for economic analysis for the cure sickle cell initiative 

We will develop a simulation model to capture the progression of patients with SCD across relevant health states over their lifetimes. Our simulation model will follow patients from the age at diagnosis over their lifetimes and will produce lifetime estimates of outcomes and costs by modeling state-specific estimates of payoffs in health and healthcare utilization.

Aim 3: Employ data visualization techniques to promote and facilitate dissemination for the MEASURE model

We will present our model and results to various public conferences and settings. We will work with the Emmes Corporation and the NIH to identify other outlets for dissemination.

One important feature of our model will be to provide a web-based R-Shiny interface for our simulation model. Using this interface, any stakeholder interested in this area can generate estimates of comparative effectiveness and cost-effectiveness by varying parameter values for certain emerging therapies as compared to standard of care. Results will be presented through this web-interface using both tables and graphs.

Anirban Basu, PhD
Scott Ramsey, MD, PhD
Beth Devine, PharmD, PhD
Douglas Barthold, PhD
Micheal A Bender, MD
Aaron Winn, PhD

Graduate students
Boshen Jiao, MPH
Kate Johnson, MSc
Zizi Elsisi, MS


Winona Wright


  1. Jiao B. Basu A, Roth J, Bender M, Rovira I, Clemons T, Quach D, Ramsey S, Devine B. The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. PharmacoEconomics  2021; 39(11):1225-1241.
  2. Quach D, Jiao B, Basu A, Bender MA, Ramsey SD, Devine B. A landscape analysis and discussion of value of gene therapies for sickle cell disease. Expert Review of Pharmacoeconomics and Outcomes Research 2022; 22(6):891-911.
  3. Jiao B, Basu A, Ramsey S, Roth J, Bender MA, Quach D, Devine B.  Health State Utilities for Sickle Cell Disease: A Catalog Prepared from a Systematic Review. Value In Health 2022; 25(2):276-287.
  4. Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Elsisi Z, Johnson KM, Cousin E, Ramsey SD, Devine B. Medical and Non-Medical Costs of Sickle Cell Disease and Treatments: A Systematic Review and Landscape Analysis. PharmacoEconomics Open 2022. 6(4):469-481.
  5. Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Advances 2022; May 16:bloodadvances.2021006281.
  6. Johnson KM, Jiao B, Bender MA, Ramsey SD, Devine B, Basu Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. PLoS One 2022 Apr 28;17(4):e0267448.
  7. Jiao B, Basu A. Associating Health-Related Quality of Life with Time Use in the United States to Inform Productivity and Time Costs Calculation in Cost-Effectiveness Analysis. PharmacoEconomics. 2023. In Press.
  8. Ramsey SD; Bender MA; Li L; Johnson KM; Jiao B; Devine B; Basu A. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance – A retrospective cohort study. PLoS One 2022. 17(11):e0278137.
  9. Jiao B, Hankins JS, Devine B, Barton M, Bender MA, Basu Mapping and validation of generic PedsQL scores to utility values for individuals with sickle cell disease. Quality of Life Research 2022; 31(9):2729-2738.
  10. Jiao B, Johnson KM, Ramsey SD, Bender MA, Devine B, Basu A. Long-Term Survival of Individuals with Sickle Cell Disease: A Nationwide Cohort Study of Medicare and Medicaid Beneficiaries. Blood Advances 2023; 7(13):3276-3283.
  11. Winn A, Basu A, Ramsey SD. A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America. PharmacoEconomics Open 2023. 7(2):313-320.
  12. Basu A, Winn AN, Johnson KM, Jiao B, Devine B, Hankins JS, Arnold SD, Bender MA, Ramsey SD. Gene therapy versus common care for eligible individuals with Sickle Cell disease in the United States: A cost-effectiveness analysis. Annals of Internal Medicine In Press.


Enter UW-MEASURE R-Shiny Platform